Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study.
Alsoud D, Sabino J, Franchimont D, Cremer A, Busschaert J, D'Heygere F, Bossuyt P, Vijverman A, Vermeire S, Ferrante M